Blog Archives

Cholangiocarcinoma: Diabetes Drugs In DPP-4 Inhibitor Class Associated With Doubled Risk

Read more ›

Tags: , , , , , , , , , , , , , , , , , , , , ,

Heart attacks and stroke: The risk of DPP-4 anti-diabetes drugs

May 06, 2018 – In April 2016 the American Food and Drug Administration (FDA) took regulatory action by mandating label changes with new warnings about an increased risk of heart failure for  new diabetes medicines in the dipeptidyl peptidase-4 (DPP-4) inhibitor drug class, including Saxagliptin (Onglyza),

Read more ›

Tags: , , , , , , , , , , , , , , , ,

Diabetes is manageable if you know how

November 14, 2017 – Diabetes is manageable if you know how

Article by author Chloe Pearson.

Article top photo Jenny Hill at Unplash.

If you have diabetes, you already know that staying healthy is going to be a challenge: Keeping track of your blood sugar,

Read more ›

Tags: , , , ,

Diabetes: Is rhabdomyolysis associated with DPP-IV inhibitors?

October 15, 2017 – According to the quarterly safety report April – June 2017 by the American Food & Drug Administration (FDA), originating from the  FDA Adverse Event Reporting System (FAERS), the class of diabetes drugs referred to as dipeptidyl peptidase-4 inhibitors (DPP-IV inhibitors) may be associated with rhabdomyolysis,

Read more ›

Tags: , , , , , , , , , , , , , , , , , , , , , , , , ,

Is there a heightened risk of heart failure with diabetes medications containing saxagliptin and alogliptin?

April o5, 2016 – There have been indications that a heightened risk of heart failure may be associated with diabetes medications containing the pharmacologically active ingredients saxagliptin or alogliptin.  In the US, this includes  the FDA-approved drugs Saxagliptin (Onglyza), Saxagliptin/Metformin (Kombiglyze XR), Alogliptin (Nesina), Alogliptin/Metformin (Kazano), and Alogliptin/Pioglitazone (Oseni).

Read more ›

Tags: , , , , , , , , , ,


Diabetes-Arzneimittel mit dem Wirkstoff Rosiglitazon – Vorgesehene Sistierung der Zulassung in der Europäischen Union.

23. September 2010 – Das Arzneimittel-Institut der Schweiz (Swissmedic) hat heute folgende Mitteilung veröffentlicht:

23.9.10. – Swissmedic.  Die Arzneimittelbehörde der EU (EMEA) sieht vor, die Zulassung der Diabetes-Medikamente mit dem Wirkstoff Rosiglitazon zu suspendieren; sie werden dort in einigen Monaten nicht mehr erhältlich sein. Mit diesem Wirkstoff sind in der Schweiz die Präparate Avandia® und Avandamet® Tabletten zugelassen (Rosiglitazon bzw.

Read more ›

Tags: , , , , ,

European Medicines Agency (EMEA) recommends withdrawal of Benfluorex from the market in European Union

December 31, 2009 – The European Medicines Agency (EMEA) has recommended the withdrawal of all medicines containing Benfluorex in the European Union, because their risks, particularly the risk of heart valve disease, are greater than their benefits.

Doctors should stop prescribing Benfluorex-containing medicines and consider alternative treatments.

Read more ›

Tags: , , , ,

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Give and take: Cancer chromosomes give the game away January 29, 2020
    Dr. Pascal Duijf from QUT's School of Biomedical Sciences and IHBI (Institute of Health and Biomedical Innovation) said the study, published in Nature Communications today, analysed chromosome arm abnormalities in more than 23,000 human tumours and 1000 cancer cell lines.
  • Single-cell sequencing of CLL therapy: Shared genetic program, patient-specific execution January 29, 2020
    Researchers at the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, the Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases in Vienna, the University Medical Center of Regensburg, and the National Institute of Hematology and Infectious Diseases and the Semmelweis University in Budapest have studied the response to targeted leukemia therapy […]
  • Are you 'at risk' of being a habitual tofu eater? January 29, 2020
    Researchers at the RIKEN Center for Integrative Medical Sciences (IMS) in Japan and colleagues at Osaka University have found genetic variations in humans related to specific dietary habits. Published in Nature Human Behaviour, the genome-wide association study found 9 gene locations associated with eating and drinking foods like meat, tofu, cheese, tea, and coffee. Among […]
  • Stem cells, CRISPR and gene sequencing technology are basis of new brain cancer model January 29, 2020
    Using genetically engineered human pluripotent stem cells, University of California San Diego School of Medicine researchers created a new type of cancer model to study in vivo how glioblastoma, the most common and aggressive form of brain cancer, develops and changes over time.
  • Treating hemophilia with gene therapy January 29, 2020
    Within the framework of an international study, Lund University and Skåne University Hospital have started treating patients with hemophilia with gene therapy, something that began in January this year. The hope is that the new treatment will significantly simplify everyday life for those with severe hemophilia.
Top